Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MedGenesis Therapeutix Inc.

http://www.medgenesis.com/

Latest From MedGenesis Therapeutix Inc.

Finance Watch: Lilly Completes Elanco Animal Health Spin-Out As New IPO Filings Keep Rising

Public Company Edition: Eli Lilly & Co. wasted no time spinning out its animal health business Elanco, which raised $1.5bn in its public debut. Also, as the biopharma IPO tally rises, Vivo Capital launches a new public life science company fund. Meanwhile, Concordia completes its recapitalization.

Financing Business Strategies

Endocyte's ABX Deal To Serve As Springboard For Radioligand Pipeline

Company gains worldwide rights to mid-stage therapy 177Lu-PSMA-617, which would compete with Bayer/Algeta's radiopharmaceutical Xofigo in metastatic castration-resistant prostate cancer.

Deals Business Strategies

Straightforward Surgery Advances Drug Delivery To The Brain

Adopting an established endoscopic nasal grafting technique, researchers at Mass Eye and Ear have shown the ability to deliver a drug across the blood-brain barrier effectively and with reduced side effects. Their work could move rapidly into clinical testing in neurodegenerative diseases and could form the basis for delivering a wide range of existing drugs as well as new compounds whose development is predicated on use of the technique.

Medical Device BioPharmaceutical

Pfizer Talks Potential Spinout, Suggests Tax-Inversion Play Still Possible

With 10 months of profit-and-loss data from its division into innovative and established product units, Pfizer will continue considering whether a spin-out into two separate companies offers shareholders the best value, CEO Read tells quarterly call. He also said tax-inversion remains a viable strategy for the pharma.

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
  • Biotechnology
    • Large Molecule
UsernamePublicRestriction

Register